ValiRx PLC VAL401 results shortly to be on ClinicalTrials.gov (0502E)
October 15 2018 - 7:00AM
UK Regulatory
TIDMVAL
RNS Number : 0502E
ValiRx PLC
15 October 2018
VALIRX PLC
("ValiRx" or the "Company")
VAL401 RESULTS TO SHORTLY BE AVAILABLE ON CLINICALTRIALS.GOV
London, UK., 15 October 2018: ValiRx Plc (AIM: VAL), the
clinical stage biotechnology company, is pleased to advise that the
results from the Phase II trial of VAL401, the anti-cancer compound
developed by ValiSeek, the joint venture between ValiRx and Tangent
Reprofiling Limited, for late stage non-small cell lung
adenocarcinoma, have been accepted for inclusion in the publicly
accessible database, ClinicalTrials.gov (NCT02875340), and will
shortly become available.
Dr Suzy Dilly, CEO of ValiSeek, commented: "The acceptance of
the results into the independent external database satisfies the
requirement to make publicly available all data from clinical
trials, providing a statement of numerical listing of data.
Although, along with the submission of the Clinical Study Report to
the Ministry of Health in Tbilisi, this concludes our formal
obligations on trial reporting, we are also in the process of
publication through peer-reviewed industry journals, which will
provide interpretation of these listed results. I look forward to
announcing the release of these further publications in due
course."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
*** ENDS ***
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008 4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008 4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879 458
364
tarquin.edwards@valirx.com
Cairn Financial Advisers LLP (Nominated Tel: +44 (0) 20 7213 0880
Adviser)
Liam Murray/Jo Turner/Richard Nash
Novum Securities Limited (Broker) Tel: +44 (0) 20 7399 9400
Colin Rowbury
Notes for Editors
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from Word class institutions, such
as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCMABLTMBABMPP
(END) Dow Jones Newswires
October 15, 2018 07:00 ET (11:00 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2023 to Apr 2024